Zhi‐Fu Tao - Concepedia

Author

Zhi‐Fu Tao

Abbott (United States)ORCID

Also Known As

Tao, Z.-F., Tao, Zhi-Fu, Z. F. Tao, Z. Tao, Z.-F. Tao, Z.‐F. TAO, Zhi-Fu Tao, Zhifu Tao, Zhihong Tao, Zhi‐Fu Tao

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Abbott (United States)Abbott Fund AbbVie (United States)Tokyo Medical and Dental University Kyoto University

About

Zhi‐Fu Tao is an author at Abbott (United States) specializing in natural sciences, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	1.2K
2	Natural Sciences	13	14	542
3	Engineering	2	2	52
4	Health Sciences	1	1	129
5	Applied Physics	1	1	14

Zhi‐Fu Tao

Publications

Citations

H-Index

Page 1

	Year	Citations
lncRNA-MIAT Regulates Microvascular Dysfunction by Functioning as a Competing Endogenous RNA Biao Yan, Jin Yao, Jingyu Liu, Circulation Research	2015	629
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy Darren C. Phillips, Michael J. Mitten, Erwin R. Boghaert, Science Translational Medicine Cancer TherapyChemoprevention StrategyBcl-2/bcl-xl/bcl-w Inhibitor Abt-263ImmunologyPharmacotherapy	2015	530
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity Zhi‐Fu Tao, Lisa Hasvold, Le Wang, ACS Medicinal Chemistry Letters	2014	328
Aberrant Expression of Long Noncoding RNAs in Early Diabetic Retinopathy Biao Yan, Zhi‐Fu Tao, Xiu‐Miao Li, Investigative Ophthalmology & Visual Science	2014	211
Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity Milan Bruncko, Le Wang, George S. Sheppard, Journal of Medicinal Chemistry Drug TargetMcl-1 InhibitorsHigh ThroughputExcellent SelectivityCancer Biology	2015	150
Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics Zehan Chen, Zhan Xiao, Wen‐Zhen Gu, International Journal of Cancer Selective Chk1 InhibitorsCell DeathCell CycleCancer BiologyTumor Biology	2006	129
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> Inhibitor Le Wang, George Doherty, Andrew S. Judd, ACS Medicinal Chemistry Letters	2020	127
Structure-Based Design, Synthesis, and Biological Evaluation of Potent and Selective Macrocyclic Checkpoint Kinase 1 Inhibitors Zhi‐Fu Tao, Le Wang, Kent D. Stewart, Journal of Medicinal Chemistry Drug TargetChemical BiologyGrubbs Metathesis MacrocyclizationPharmaceutical ChemistryTumor Biology	2007	88
Discovery of 3<i>H</i>-Benzo[4,5]thieno[3,2-<i>d</i>]pyrimidin-4-ones as Potent, Highly Selective, and Orally Bioavailable Inhibitors of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM) Kinases Zhi‐Fu Tao, Lisa Hasvold, Edward K. Han, Journal of Medicinal Chemistry	2009	84
Naphthalimide hydroperoxides as photonucleases: substituent effects and structural basis Zhi‐Fu Tao, Xuhong Qian Dyes and Pigments BiochemistryPhotochemistryRadical (Chemistry)PhototoxicityStructural Basis	1999	73

Page 1